Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
Caladrius Biosciences Q2 EPS $(0.11) Misses $(0.10) Estimate
Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease over losses of $(0.10) per share from
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Earnings Outlook For Caladrius Biosciences
Caladrius Biosciences (NASDAQ:CLBS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement.
Analysts estimate that Caladrius Biosciences will report an earnings per share (EPS) of $-0.10.
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and…
Caladrius Biosciences And Cend Therapeutics Highlights Publication Of Pancreatic Cancer Trial Data In The Lancet Gastroenterology And Hepatology
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, and Cend
The Daily Biotech Pulse: INmune Bio’s Planned Alzheimer’s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours:
Caladrius Biosciences Q1 EPS $(0.07) Beats $(0.10) Estimate
Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 30 percent. This is a 63.16 percent increase over losses of $(0.19) per share
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
